Article
Prodizen provides training on next-generation regenerative medicine technology, the first of its kind in Korea, to North American buyers.
- 작성일 : 2025.12.04
- 조회수 : 10
Cameron World PRP CEO (center) is observing a treatment by Hoan Clinic Director Choi Jun-ho (bottom left).
Domestic patent-holding GFC platform accelerates global clinical application
[Edaily Reporter Lee Jeong-hoon] Prodigen Co., Ltd. (CEO Shim Soo-ja), a regenerative medicine company, announced on the 4th that it successfully conducted a training program on its "next-generation growth factor concentrate technology, GFC (Growth Factor Concentrate)," inviting representatives from the Canadian company WorldPRP (Clarion Medical Technologies).
This training session, designed to provide first-hand experience of how Prodizen's core technology, the GFC kit, first developed in Korea last year, is applied in actual clinical settings, met with strong interest from overseas buyers.
Notably, the delegation visited HOAN Clinic, a partner medical institution of Prodizen, during their training program and directly observed the entire process of blood collection, separation, concentration, and treatment preparation using the GFC+ kit. They then listened to an on-site explanation of the GFC+ kit's high-concentration growth factor extraction performance, precise separation and concentration process, and cell activation mechanisms applied to anti-aging treatments, confirming the true state of Korean regenerative medicine technology.
Hoan Clinic, located in Gangnam, Seoul, recently garnered attention when world-famous celebrity Kim Kardashian received skin regeneration treatment during her visit to Korea. It is a collaborative medical institution that has been jointly applying Prodizen and GFC-based regenerative treatment protocols.
Last year, Prodizen first applied GFC in Korea, a technology that represents a step forward from conventional PRP. While PRP concentrates platelets, GFC extracts and concentrates growth factors at high concentrations, along with platelets. As a result, growth factor concentrations are two to five times higher than in PRP, while minimizing the risk of side effects. Prodizen holds key patents for implementing GFC, including the selective concentration of growth factors and the separation and connector structure for removing unnecessary components.
Prodizen is a first-generation regenerative medicine company that developed and commercialized Korea's first PRP (platelet-rich plasma) kit in 2008. It has passed the Ministry of Health and Welfare's New Medical Technology Assessment for epicondylitis treatment in 2019, autologous platelet-rich plasma eye drop treatment in 2021, and infertility treatment in 2022. It has received FDA, CE, and CFDA certifications in the US, and currently supplies its products to over 30 countries.
Prodizen CEO Shim Su-ja said, “Prodizen’s GFC technology is a comprehensive regenerative medicine solution that combines 17 years of accumulated clinical know-how and manufacturing technology,” and added, “We will become a company that exports regenerative treatment standards, not just products.”
He added, “As we have patents related to GFC technology in Korea, we will create a structure where medical professionals around the world can learn from Korea and Korean technology can become the standard treatment in global clinical settings.”
다음글